NexgenRx Third Quarter 2024 Earnings: EPS: CA$0.002 (vs CA$0.002 loss in 3Q 2023)

NexgenRx (CVE:NXG) Third Quarter 2024 Results

Key Financial Results

• Revenue: CA$4.16m (up 23% from 3Q 2023).
• Net income: CA$149.2k (up from CA$130.7k loss in 3Q 2023).
• Profit margin: 3.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.
• EPS: CA$0.002 (up from CA$0.002 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

NexgenRx shares are down 1.7% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for NexgenRx (2 don't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.